(URGN) UroGen Pharma - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 916m USD | Total Return: 129.7% in 12m

Cancer Drugs, Hydrogel Technology, Specialty Cancers
Total Rating 42
Safety 24
Buy Signal 0.11
Biotechnology
Industry Rotation: -3.7
Market Cap: 916M
Avg Turnover: 13.7M USD
ATR: 5.78%
Peers RS (IBD): 53.3
Risk 5d forecast
Volatility80.8%
Rel. Tail Risk-21.7%
Reward TTM
Sharpe Ratio1.19
Alpha86.41
Character TTM
Beta0.955
Beta Downside1.455
Drawdowns 3y
Max DD82.64%
CAGR/Max DD0.38
EPS (Earnings per Share) EPS (Earnings per Share) of URGN over the last years for every Quarter: "2021-03": -1.17, "2021-06": -1.17, "2021-09": -1.35, "2021-12": -1.27, "2022-03": -1.25, "2022-06": -1.18, "2022-09": -1.13, "2022-12": -1.22, "2023-03": -1.3, "2023-06": -1.03, "2023-09": -0.68, "2023-12": -0.72, "2024-03": -0.97, "2024-06": -0.91, "2024-09": -0.55, "2024-12": -0.8, "2025-03": -0.92, "2025-06": -1.05, "2025-09": -0.69, "2025-12": -0.53, "2026-03": 0,
EPS CAGR: 65.26%
EPS Trend: 71.4%
Last SUE: 3.24
Qual. Beats: 1
Revenue Revenue of URGN over the last years for every Quarter: 2021-03: 7.485, 2021-06: 13.032, 2021-09: 11.351, 2021-12: 16.174, 2022-03: 13.564, 2022-06: 16.604, 2022-09: 16.097, 2022-12: 18.092, 2023-03: 17.192, 2023-06: 21.139, 2023-09: 20.852, 2023-12: 23.53, 2024-03: 18.781, 2024-06: 21.848, 2024-09: 25.204, 2024-12: 24.565, 2025-03: 20.254, 2025-06: 24.215, 2025-09: 27.482, 2025-12: 37.837, 2026-03: null,
Rev. CAGR: 31.46%
Rev. Trend: 88.3%
Last SUE: -0.95
Qual. Beats: 0

Warnings

Negative Equity with losses - insolvent profile

Interest Coverage Ratio -4.1 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: URGN UroGen Pharma

UroGen Pharma Ltd. (URGN) develops and commercializes treatments for urothelial and specialty cancers. The company utilizes its proprietary RTGel technology, a reverse thermal gelation hydrogel, in its product offerings.

Its primary product is Jelmyto, a pyelocalyceal solution. The pipeline includes UGN-102, UGN-103, and UGN-104, all in various stages of clinical trials for non-muscle invasive urothelial cancers, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer. The biotechnology sector often focuses on developing novel therapeutic agents for unmet medical needs.

URGN is also advancing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine for high-grade non-muscle invasive bladder cancer, currently in Phase 1 trials. The companys business model includes strategic partnerships, exemplified by agreements with Agenus Inc. for urinary tract cancer treatments and with medac Gesellschaft für klinische Spezialpräparate m.b.H. for UGN-103 and UGN-104 development. Further research on ValueRay can provide more detailed insights into URGNs financial performance and market position.

Headlines to Watch Out For
  • Jelmyto sales drive current revenue growth
  • UGN-102 clinical trial results impact future pipeline
  • Regulatory approvals critical for new product launches
  • Licensing agreements expand market reach and product development
Piotroski VR‑10 (Strict) 2.0
Net Income: -153.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.81 > 0.02 and ΔFCF/TA -47.21 > 1.0
NWC/Revenue: 127.2% < 20% (prev 254.6%; Δ -127.5% < -1%)
CFO/TA -0.81 > 3% & CFO -162.4m > Net Income -153.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.01 > 1.5 & < 3
Outstanding Shares: last quarter (49.2m) vs 12m ago 4.68% < -2%
Gross Margin: 88.66% > 18% (prev 0.90%; Δ 8.78k% > 0.5%)
Asset Turnover: 45.16% > 50% (prev 31.64%; Δ 13.53% > 0%)
Interest Coverage Ratio: -4.08 > 6 (EBITDA TTM -135.7m / Interest Expense TTM 33.8m)
Altman Z'' -15.00
A: 0.70 (Total Current Assets 186.0m - Total Current Liabilities 46.4m) / Total Assets 200.5m
B: -4.79 (Retained Earnings -959.7m / Total Assets 200.5m)
C: -0.57 (EBIT TTM -138.1m / Avg Total Assets 243.1m)
D: -3.14 (Book Value of Equity -959.6m / Total Liabilities 305.9m)
Altman-Z'' Score: -18.15 = D
Beneish M -2.34
DSRI: 1.34 (Receivables 33.1m/20.3m, Revenue 109.8m/90.4m)
GMI: 1.02 (GM 88.66% / 90.18%)
AQI: 1.31 (AQ_t 0.03 / AQ_t-1 0.02)
SGI: 1.21 (Revenue 109.8m / 90.4m)
TATA: 0.04 (NI -153.5m - CFO -162.4m) / TA 200.5m)
Beneish M-Score: -2.34 (Cap -4..+1) = BBB
What is the price of URGN shares? As of April 12, 2026, the stock is trading at USD 21.57 with a total of 1,046,102 shares traded.
Over the past week, the price has changed by +15.91%, over one month by +10.90%, over three months by +0.56% and over the past year by +129.71%.
Is URGN a buy, sell or hold? UroGen Pharma has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy URGN.
  • StrongBuy: 5
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the URGN price?
Analysts Target Price 35.6 65.2%
UroGen Pharma (URGN) - Fundamental Data Overview as of 12 April 2026
P/S = 8.3452
P/B = 16.2331
Revenue TTM = 109.8m USD
EBIT TTM = -138.1m USD
EBITDA TTM = -135.7m USD
Long Term Debt = 122.2m USD (from longTermDebt, last quarter)
Short Term Debt = 1.59m USD (from shortTermDebt, two quarters ago)
Debt = 128.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 17.6m USD (from netDebt column, last quarter)
Enterprise Value = 924.1m USD (916.2m + Debt 128.3m - CCE 120.5m)
Interest Coverage Ratio = -4.08 (Ebit TTM -138.1m / Interest Expense TTM 33.8m)
EV/FCF = -5.68x (Enterprise Value 924.1m / FCF TTM -162.7m)
FCF Yield = -17.61% (FCF TTM -162.7m / Enterprise Value 924.1m)
 FCF Margin = -148.2% (FCF TTM -162.7m / Revenue TTM 109.8m)
 Net Margin = -139.8% (Net Income TTM -153.5m / Revenue TTM 109.8m)
Gross Margin = 88.66% ((Revenue TTM 109.8m - Cost of Revenue TTM 12.4m) / Revenue TTM)
Gross Margin QoQ = 91.31% (prev 88.07%)
Tobins Q-Ratio = 4.61 (Enterprise Value 924.1m / Total Assets 200.5m)
Interest Expense / Debt = 10.14% (Interest Expense 13.0m / Debt 128.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -109.1m (EBIT -138.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.01 (Total Current Assets 186.0m / Total Current Liabilities 46.4m)
 Debt / Equity = -1.22 (negative equity) (Debt 128.3m / totalStockholderEquity, last quarter -105.5m)
 Debt / EBITDA = -0.13 (negative EBITDA) (Net Debt 17.6m / EBITDA -135.7m)
 Debt / FCF = -0.11 (negative FCF - burning cash) (Net Debt 17.6m / FCF TTM -162.7m)
 Total Stockholder Equity = -90.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.14% (Net Income -153.5m / Total Assets 200.5m)
 RoE = 170.2% (negative equity) (Net Income TTM -153.5m / Total Stockholder Equity -90.2m)
 RoCE = -431.1% (out of range, set to none) (EBIT -138.1m / Capital Employed (Equity -90.2m + L.T.Debt 122.2m))
 RoIC = -340.3% (out of range, set to none) (NOPAT -109.1m / Invested Capital 32.1m)
 WACC = 9.18% (E(916.2m)/V(1.04b) * Re(9.34%) + D(128.3m)/V(1.04b) * Rd(10.14%) * (1-Tc(0.21)))
Discount Rate = 9.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 16.69%
 [DCF] Fair Price = unknown (Cash Flow -162.7m)
 EPS Correlation: 71.45 | EPS CAGR: 65.26% | SUE: 3.24 | # QB: 1
Revenue Correlation: 88.26 | Revenue CAGR: 31.46% | SUE: -0.95 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.37 | Chg7d=+0.000 | Chg30d=-0.056 | Revisions Net=-3 | Analysts=8
EPS current Year (2026-12-31): EPS=-1.17 | Chg7d=+0.000 | Chg30d=-0.198 | Revisions Net=-1 | Growth EPS=+63.4% | Growth Revenue=+122.7%
EPS next Year (2027-12-31): EPS=0.92 | Chg7d=+0.000 | Chg30d=-0.485 | Revisions Net=-2 | Growth EPS=+179.1% | Growth Revenue=+73.8%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle